Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Gianfranco Ferraccioli

doi:10.1136/annrheumdis-2012-202470

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Gianfranco Ferraccioli

Risultato della ricerca: Contributo in rivista › Articolo in rivista

65 Citazioni (Scopus)

Abstract

Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.

Lingua originale	English
pagine (da-a)	583-589
Numero di pagine	7
Rivista	EARD
Volume	72
DOI	https://doi.org/10.1136/annrheumdis-2012-202470
Stato di pubblicazione	Pubblicato - 2013
Pubblicato esternamente	Sì

Keywords

Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Arthritis, Juvenile
Arthritis, Rheumatoid
Consensus
Humans
Interleukin-6
Spondylitis, Ankylosing

Accesso al documento

10.1136/annrheumdis-2012-202470

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{ab929cb3e1fb448ba1c61cfb59456dd7,

title = "Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement",

abstract = "Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.",

keywords = "Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Juvenile, Arthritis, Rheumatoid, Consensus, Humans, Interleukin-6, Spondylitis, Ankylosing, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Juvenile, Arthritis, Rheumatoid, Consensus, Humans, Interleukin-6, Spondylitis, Ankylosing",

author = "Gianfranco Ferraccioli",

year = "2013",

doi = "10.1136/annrheumdis-2012-202470",

language = "English",

volume = "72",

pages = "583--589",

journal = "EARD",

issn = "1468-2060",

publisher = "London: BMJ Publishing.",

}

TY - JOUR

T1 - Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

AU - Ferraccioli, Gianfranco

PY - 2013

Y1 - 2013

N2 - Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.

AB - Suppression of the immunoinflammatory cascade by targeting interleukin 6 (IL-6) mediated effects constitutes a therapeutic option for chronic inflammatory diseases. Tocilizumab is the only IL-6 inhibitor (IL-6i) licensed for rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), but also other agents targeting either IL-6 or its receptor are investigated in various indications.

KW - Antibodies, Monoclonal, Humanized

KW - Antirheumatic Agents

KW - Arthritis, Juvenile

KW - Arthritis, Rheumatoid

KW - Consensus

KW - Humans

KW - Interleukin-6

KW - Spondylitis, Ankylosing

KW - Antibodies, Monoclonal, Humanized

KW - Antirheumatic Agents

KW - Arthritis, Juvenile

KW - Arthritis, Rheumatoid

KW - Consensus

KW - Humans

KW - Interleukin-6

KW - Spondylitis, Ankylosing

UR - http://hdl.handle.net/10807/54001

U2 - 10.1136/annrheumdis-2012-202470

DO - 10.1136/annrheumdis-2012-202470

M3 - Article

SN - 1468-2060

VL - 72

SP - 583

EP - 589

JO - EARD

JF - EARD

ER -

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo